Ibrutinib Resistance Is Reduced by an Inhibitor of Fatty Acid Oxidation in Primary CLL Lymphocytes.Published in:Frontiers in Oncology, 2018, p. N.PAG, doi. 10.3389/fonc.2018.00411By:Galicia-Vázquez, Gabriela;Aloyz, RaquelPublication type:Article